Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey


Kilickap S., Demirci U., Bugdayci F., Tural D., Korkmaz T., Paydas S., ...Daha Fazla

JOURNAL OF THORACIC ONCOLOGY, cilt.14, 2019 (SCI İndekslerine Giren Dergi) identifier